- Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
- The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021
- Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed to help people with diabetes and prediabetes manage their glucose levels.
Nemaura Medical’s management recently revealed their attendance at the 23rd Annual H.C. Wainwright Global Investment Conference, held in an entirely digital forum between September 13-15, 2021 (https://ibn.fm/1OiBy). Initially founded in 1868, H.C. Wainwright is a U.S.-based investment bank offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions.
The 23rd Annual H.C. Wainwright Global Investment Conference (https://ibn.fm/x6vUI) featured over 850 corporates in attendance, distributed across six distinctive sector tracks, namely – healthcare & life sciences; metals & mining; cryptocurrency, blockchain, & fintech; cleantech; technology, media & telecommunications; as well as shipping & maritime. In addition, the conference featured some of the industry’s leading keynote speakers, one-on-one investor meetings, and networking opportunities with attendees. H.C. Wainwright’s annual investment conference routinely attracts some of North America’s largest institutional investors, private equity firms, and venture capitalists seeking new investment opportunities.
Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. In the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/pVi34).
Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable, and flexible method of blood glucose tracking for improved diabetes management. NMRD has positioned itself at the intersection of the global Type 2 diabetes market, which is expected to reach an annual value of nearly $59 billion by 2025. Moreover, the product also allows the company to participate in the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is forecast to hit $60 billion by 2023.
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
